GlassScriptPhysician profile
Frederic Rene Martin
NPI 1265582605
$5,849.93
in general payments reported to CMS, 2019-2025
40 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $922 · 2021: $1,139 · 2022: $1,062 · 2023: $786 · 2024: $888 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244 · Education: $26.73 · Travel and Lodging: $19.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.66 |
| Education | $26.73 |
| Travel and Lodging | $19.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $924.69 | 2021-2025 | |
| Biogen, INC. | $816.33 | 2019-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $466.62 | 2020-2025 | Kisunla, Emgality, Reyvow |
| Pfizer INC. | $446.15 | 2023-2025 | |
| Ucb, INC. | $363.36 | 2019-2025 | Briviact |
| Vanda Pharmaceuticals INC. | $319.33 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $259.15 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $216.05 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $181.45 | 2022 | |
| Allergan, INC. | $180.06 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.97 | 2020-2023 | Gammagard |
| Lundbeck LLC | $131.11 | 2020-2025 | Vyepti |
| Eisai INC. | $128.67 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $114.53 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $97.45 | 2020-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederic Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.